APA (7th ed.) Citation

Kuruvilla, J., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N. A., . . . Zinzani, P. L. (2021). Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study. The lancet oncology, 22(4), 512-524. https://doi.org/10.1016/S1470-2045(21)00005-X

Chicago Style (17th ed.) Citation

Kuruvilla, John, et al. "Pembrolizumab Versus Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE-204): An Interim Analysis of a Multicentre, Randomised, Open-label, Phase 3 Study." The Lancet Oncology 22, no. 4 (2021): 512-524. https://doi.org/10.1016/S1470-2045(21)00005-X.

MLA (9th ed.) Citation

Kuruvilla, John, et al. "Pembrolizumab Versus Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE-204): An Interim Analysis of a Multicentre, Randomised, Open-label, Phase 3 Study." The Lancet Oncology, vol. 22, no. 4, 2021, pp. 512-524, https://doi.org/10.1016/S1470-2045(21)00005-X.